Pharma Companies Report Promising Phase 2 Trial Results

Crinetics and Celldex reported promising phase 2 trial results for their respective treatments. Crinetics' treatment demonstrated positive long-term results, while Celldex's treatment showed sustained off-treatment improvement in patients with chronic spontaneous urticaria. Rhythm, Incyte, and Crinetics are also reporting results. Two phase 3 trials are ongoing for Celldex's treatment.

A cluster of clinical-stage and commercial biopharma names posted positive mid-stage data this week. CLDX reported long-term Phase 2 results for barzolvolimab in chronic spontaneous urticaria, showing sustained off-treatment improvement: up to 64% of patients with baseline angioedema remained angioedema-free at Week 76, with benefits persisting roughly seven months after final dosing .

CRNX presented full Phase 2 results for atumelnant in congenital adrenal hyperplasia, while RYTM and INCY also flagged encouraging early-stage readouts across their respective programs . Taken together, the updates point toward a potential shift in several chronic conditions from symptom control toward durable disease modification.

The market read-through is in the de-risking of late-stage pipelines: Celldex has two ongoing Phase 3 studies enrolling 1,939 patients, with topline data expected in Q4 2026 . Mid-stage results are not confirmatory, but consistent durability signals could support partnering interest and shape competitive positioning in allergy and rare-endocrine indications.